Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.8740
+0.0090 (1.04%)
At close: Jun 4, 2025, 4:00 PM
0.9400
+0.0660 (7.55%)
Pre-market: Jun 5, 2025, 8:16 AM EDT

Citius Pharmaceuticals Income Statement

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Mar '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 2015 - 2019
Selling, General & Admin
31.4130.0921.9115.6611.298.9
Upgrade
Research & Development
11.5711.9114.8217.6612.248.81
Upgrade
Operating Expenses
42.984236.7333.3223.5317.71
Upgrade
Operating Income
-42.98-42-36.73-33.32-23.53-17.71
Upgrade
Interest Expense
-----0.01-0.02
Upgrade
Interest & Investment Income
0.360.761.180.250.260.07
Upgrade
Other Non Operating Income (Expenses)
-----0.11
Upgrade
EBT Excluding Unusual Items
-42.63-41.24-35.55-33.06-23.28-17.55
Upgrade
Gain (Loss) on Sale of Assets
-2.393.59---
Upgrade
Other Unusual Items
----0.23-
Upgrade
Pretax Income
-42.63-38.85-31.97-33.06-23.05-17.55
Upgrade
Income Tax Expense
0.820.580.580.58--
Upgrade
Earnings From Continuing Operations
-43.44-39.43-32.54-33.64-23.05-17.55
Upgrade
Minority Interest in Earnings
1.40.29----
Upgrade
Net Income
-42.05-39.14-32.54-33.64-23.05-17.55
Upgrade
Preferred Dividends & Other Adjustments
1.051.051.15-1.45-
Upgrade
Net Income to Common
-43.1-40.19-33.69-33.64-24.51-17.55
Upgrade
Shares Outstanding (Basic)
876642
Upgrade
Shares Outstanding (Diluted)
876642
Upgrade
Shares Change (YoY)
19.89%11.16%3.57%34.52%177.28%94.25%
Upgrade
EPS (Basic)
-5.70-5.97-5.57-5.76-5.64-11.20
Upgrade
EPS (Diluted)
-5.70-5.97-5.57-5.76-5.64-11.20
Upgrade
Free Cash Flow
-23.55-28.2-29.06-28.36-24.26-16.93
Upgrade
Free Cash Flow Per Share
-3.11-4.19-4.80-4.85-5.58-10.81
Upgrade
EBITDA
-42.98-41.99-36.73-33.31-23.53-17.71
Upgrade
D&A For EBITDA
000000
Upgrade
EBIT
-42.98-42-36.73-33.32-23.53-17.71
Upgrade
Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q